Literature DB >> 2868749

D-glucaric acid excretion in critical care patients--comparison with 6 beta-hydroxycortisol excretion and serum gamma-glutamyltranspeptidase activity and relation to multiple drug therapy.

G Heinemeyer, I Roots, P Lestau, H R Klaiber, R Dennhardt.   

Abstract

The incidence of increased drug metabolism activity as a consequence of multiple drug therapy at a surgical intensive care ward has been studied non-invasively by determinations of daily urinary D-glucaric acid (GA) excretion rates. Among 165 randomly selected patients, GA excretion was stimulated in 76 cases (= 46%). Exploratory data analysis showed that increases in GA excretion are primarily due to administration of barbiturates (pentobarbitone, Nembutal), miconazole (Daktar) and, to a lesser extent, neuroleptics. Surprisingly, the large number of simultaneously administered additional drugs failed to increase GA excretion. Urinary 6 beta-hydroxycortisol (6 beta-OHF) and 17-hydroxycorticosteroid (17-OHCS) excretion rates were correlated in 34 patients with GA excretion; patients not receiving known enzyme inducers showed low GA values but high 6 beta-OHF and 17-OHCS values, however, with a ratio of 6 beta-OHF/17-OHCS in the normal range. Patients receiving high dose pentobarbitone treatment failed to exhibit significantly increased 6 beta-OHF and 17-OHCS or 6 beta-OHF/17-OHCS values. Miconazole treatment resulted in a significantly increased ratio of 6 beta-OHF/17-OHCS. gamma-Glutamyltranspeptidase activity in serum showed no correlation with GA excretion (n = 91).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2868749      PMCID: PMC1400808          DOI: 10.1111/j.1365-2125.1986.tb02817.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  29 in total

1.  The antipyrine test in clinical pharmacology: conceptions and misconceptions.

Authors:  E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

2.  Studies on the disposition of antipyrine, aminopyrine, and phenacetin using plasma, saliva, and urine.

Authors:  E S Vesell; G T Passananti; P A Glenwright; B H Dvorchik
Journal:  Clin Pharmacol Ther       Date:  1975-09       Impact factor: 6.875

3.  ALTERED CORTISOL METABOLISM IN ADVANCED CANCER AND OTHER TERMINAL ILLNESSES: EXCRETION OF 6-HYDROXYCORTISOL.

Authors:  E E WERK; J MACGEE; L J SHOLITON
Journal:  Metabolism       Date:  1964-12       Impact factor: 8.694

4.  The effect of repeated administration of diftalone on enzyme induction.

Authors:  J C Garnham; L Saunders; D M Stainton-Ellis; C Franklin; G Volans; P Turner; T Natunen
Journal:  J Pharm Pharmacol       Date:  1978-07       Impact factor: 3.765

5.  Evaluation of in vivo parameters of drug metabolizing enzyme activity in man after administration of clemastine, phenobarbital or placebo.

Authors:  A G Hildebrandt; I Roots; M Speck; K Saalfrank; H Kewitz
Journal:  Eur J Clin Pharmacol       Date:  1975-06-13       Impact factor: 2.953

6.  Prediction of drug oxidation rates in man: lack of correlation with serum gamma-glutamyl transpeptidase and urinary excretion of D-glucaric acid and 6 beta-hydroxycortisol.

Authors:  S E Smith; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

7.  Glucaric acid as an indicator of use of enzyme-inducing drugs.

Authors:  E A Sotaniemi; F Medzihradsky; G Eliasson
Journal:  Clin Pharmacol Ther       Date:  1974-04       Impact factor: 6.875

8.  Hexobarbitone disposition at different stages of intensive care treatment.

Authors:  I Rietbrock; G Lazarus; E Richter; D D Breimer
Journal:  Br J Anaesth       Date:  1981-03       Impact factor: 9.166

9.  Urinary excretion of D-glucaric acid, an indicator of drug metabolizing enzyme activity, in patients with impaired renal function.

Authors:  D Kampf; I Roots; A G Hildebrandt
Journal:  Eur J Clin Pharmacol       Date:  1980-10       Impact factor: 2.953

10.  Hepatic enzyme induction patterns and phenothiazine side effects.

Authors:  J H Wright; S B Whitaker; C B Welch; D N Teller
Journal:  Clin Pharmacol Ther       Date:  1983-10       Impact factor: 6.875

View more
  10 in total

1.  Clearance of ceftriaxone in critical care patients with acute renal failure.

Authors:  G Heinemeyer; J Link; W Weber; V Meschede; I Roots
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

Review 2.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

Review 3.  Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders.

Authors:  A Fitton; L Wiseman
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

4.  The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction.

Authors:  C Ged; J M Rouillon; L Pichard; J Combalbert; N Bressot; P Bories; H Michel; P Beaune; P Maurel
Journal:  Br J Clin Pharmacol       Date:  1989-10       Impact factor: 4.335

Review 5.  Clinical pharmacokinetic considerations in the treatment of increased intracranial pressure.

Authors:  G Heinemeyer
Journal:  Clin Pharmacokinet       Date:  1987-07       Impact factor: 6.447

Review 6.  Drug interactions with St John's wort : mechanisms and clinical implications.

Authors:  Marcus Mannel
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

7.  Kinetics of hexobarbital and dipyrone in critical care patients receiving high-dose pentobarbital.

Authors:  G Heinemeyer; H J Gramm; W Simgen; R Dennhardt; I Roots
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 8.  Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

Authors:  M M Galteau; F Shamsa
Journal:  Eur J Clin Pharmacol       Date:  2003-11-06       Impact factor: 2.953

9.  Lansoprazole does not affect the bioavailability of oral contraceptives.

Authors:  W Fuchs; R Sennewald; U Klotz
Journal:  Br J Clin Pharmacol       Date:  1994-10       Impact factor: 4.335

10.  The kinetics of metamizol and its metabolites in critical-care patients with acute renal dysfunction.

Authors:  G Heinemeyer; H J Gramm; I Roots; R Dennhardt; W Simgen
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.